Kadcyla (ado-trastuzumab emtansine) Patient Assistance Program
Don’t let the high cost of brand specialty HER2-targeted antibody-drug conjugate stand between you and the treatment you need. We help eligible patients access Kadcyla (ado-trastuzumab emtansine) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Kadcyla (ado-trastuzumab emtansine, T-DM1) is FDA-approved as adjuvant therapy for HER2-positive early breast cancer with residual invasive disease after neoadjuvant taxane and trastuzumab-based therapy, and for the treatment of HER2-positive metastatic breast cancer in patients who previously received trastuzumab and a taxane.
- Without assistance, Kadcyla costs approximately $11,000–$15,000+ per IV infusion at the standard 3.6 mg/kg dose given every 3 weeks. A full adjuvant course of 14 cycles can total $150,000+.
- Through AffordMyPrescriptions, qualifying patients can access Kadcyla coverage for a flat $69.95 per month — our advocacy team manages the entire enrollment, infusions, and renewal process.
- There is no biosimilar version of Kadcyla available in the U.S. as of 2026.
What Is Kadcyla Prescription Assistance Program?
The Kadcyla Prescription Assistance Program is a manufacturer-sponsored initiative that provides Kadcyla infusions at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for HER2+ breast cancer patients who are uninsured or underinsured, as well as Medicare beneficiaries.
Navigating the program on your own means dealing with eligibility verification, oncology-team coordination, HER2 testing documentation, prior-authorization documentation, infusion scheduling, cardiac monitoring schedules, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing infusion-schedule coordination and annual re-certification — so you focus on your treatment, not paperwork.
Pharmacy Price Comparison
- Without assistance, Kadcyla infusions cost roughly $11,000–$15,000+ each. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Per IV infusion (typical) | ~$13,000.00 | Save ~$12,930/dose |
| Higher-weight patient | ~$15,000.00 | Save ~$14,930/dose |
| Per cycle (every 3 weeks) | ~$13,000+ | Save ~$12,930/cycle |
| Full 14-cycle adjuvant course | ~$180,000+ | Save ~$179,000+ total |
| Annual cost (metastatic) | ~$220,000+ | Save ~$219,000+/yr |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Kadcyla Prescription Program?
The Patient Assistance Program is free to apply for and provides Kadcyla infusions at little or no medication cost if approved. But the process involves detailed applications, oncology-team coordination, HER2 testing documentation, infusion scheduling, cardiac monitoring (echocardiograms or MUGA scans), and ongoing renewal management. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Kadcyla:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
- Still $11,000–$15,000+ per infusion per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Kadcyla assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Kadcyla Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Kadcyla:
Kadcyla (ado-trastuzumab emtansine, also known as T-DM1) is an intravenous (IV) HER2-targeted antibody-drug conjugate (ADC) used to treat HER2-positive breast cancer — both as adjuvant therapy after surgery in patients with residual disease following neoadjuvant therapy, and for HER2-positive metastatic breast cancer that has progressed on prior trastuzumab and a taxane.
How Kadcyla Works:
Kadcyla acts as a targeted chemotherapy delivery vehicle by combining the HER2-targeting antibody trastuzumab with a potent chemotherapy drug called DM1. The antibody portion attaches to HER2-positive cancer cells, allowing the entire molecule to enter the cell and release the chemotherapy directly inside. This specialized mechanism kills cancer cells from within while largely sparing healthy tissue, providing higher efficacy than traditional chemotherapy.
Form and use:
This medication is administered as an intravenous (IV) infusion every three weeks in a clinical or hospital setting. The weight-based dosage is typically given over 90 minutes for the first session and can be shortened to 30 minutes for subsequent doses if well-tolerated. For early breast cancer, treatment usually lasts for 14 cycles, while metastatic cases continue until the disease progresses or toxicity occurs.
Generic availability:
As of 2026, there is no FDA-approved biosimilar version of Kadcyla available in the United States. While other HER2-targeted antibody-drug conjugates like Enhertu have been approved for similar conditions, Kadcyla remains a unique branded therapy. The choice between these advanced treatments depends on a patient’s specific indication and prior treatment history as determined by an oncology team.
Warnings:
Kadcyla carries serious boxed warnings for liver injury, heart muscle weakness (cardiomyopathy), and embryo-fetal toxicity. Patients must undergo regular liver-function tests and cardiac monitoring before every treatment cycle to ensure safety. Other notable risks include lung inflammation, low platelet counts, and nerve damage; any symptoms like jaundice, bruising, or shortness of breath should be reported immediately.
FAQ (Frequently Asked Questions)
How Much Does Kadcyla Cost Without Insurance?
Per-infusion costs commonly run $11,000–$15,000+ at the standard 3.6 mg/kg dose every 3 weeks. A full 14-cycle adjuvant course can total $150,000+. Through AffordMyPrescriptions, qualifying patients receive Kadcyla at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
How Is Kadcyla Different From Herceptin?
Both target HER2, but Kadcyla is an antibody-drug conjugate (ADC) — it combines trastuzumab (the antibody in Herceptin) with a potent chemotherapy molecule called DM1. Kadcyla delivers chemotherapy directly into HER2-expressing cancer cells, providing greater efficacy than Herceptin alone but with a different side-effect profile (including more thrombocytopenia and a higher risk of liver toxicity).
Why Is Cardiac Monitoring Required?
Like Herceptin, Kadcyla can cause cardiomyopathy (weakening of the heart muscle). Cardiac function (LVEF) is assessed at baseline and before each cycle with echocardiogram or MUGA scan. Most cases are reversible if caught early and treatment is paused or stopped.
Is There A Biosimilar Or Cheaper Alternative?
There is no biosimilar to Kadcyla in the U.S. as of 2026. Other HER2-targeted ADCs (Enhertu/trastuzumab deruxtecan) are FDA-approved for some HER2-positive cancers — whether one is a better clinical fit depends on the indication, prior treatments, and tolerability. We mention this directly because if a different therapy on a more accessible assistance pathway would work, that may be a better path.
How Long Will I Need Kadcyla?
For early-stage breast cancer adjuvant therapy (after neoadjuvant treatment), Kadcyla is given for 14 cycles (approximately 9–10 months). For metastatic disease, treatment continues until progression or unacceptable toxicity.
What If My Application Is Denied?
If your initial application is denied, we explore alternatives — the manufacturer’s copay assistance program if you have commercial insurance, independent foundations such as the PAN Foundation, HealthWell Foundation, Susan G. Komen, or Living Beyond Breast Cancer, or asking your oncology team whether a different HER2-targeted therapy would be appropriate. If we cannot find a path, you will not be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Kadcyla, our team may be able to help you access assistance programs designed to make brand specialty HER2-targeted ADC therapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.